Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...
PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...
on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC). Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in ...
The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...
in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Also Read: Pfizer Q4 ...
The data cutoff date for the current analysis of the study was August 8, 2024. With 29.1 months of median follow-up, 12% of ...
PRINCETON, N.J. - UroGen Pharma Ltd. (NASDAQ: URGN), a biotech company focusing on urothelial and specialty cancer treatments with impressive gross profit margins of 90%, recently shared long-term ...
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback